Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Medically reviewed by Kathleen Daly, MD Schizoid personality disorder (ScPD) causes traits like having few social ...

The death of a mother at the hands of her son was described as “tragic” by a Calgary judge, who found the 32-year-old not criminally responsible.

I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically ...

Sonoma County is among 50 counties due to implement CARE Court by Dec. 1. The program is meant to address the state’s most ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI), Tuesday announced positive data from phase 3 trial of Lumateperone, marketed as Caplyta, for the prevention of relapse in adult patients with ...

For years, due to untreated schizophrenia, I refused housing, preferring to be homeless. When dealing with the severely ...

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

Recently, a joint research team from Korea University and Yonsei University announced that women with schizophrenia have a ...